Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Rhea-AI Summary

Adicet Bio (Nasdaq: ACET), a clinical-stage biotech firm specializing in gamma delta T cell therapies for autoimmune diseases and cancer, will present preclinical data on ADI-270 at the 2024 European Hematology Association (EHA) Hybrid Congress. The event, held in Madrid, Spain from June 13-16, 2024, will feature Yvan Chanthery, Ph.D., presenting on June 14 at 18:00 CEST. ADI-270 is an armored allogeneic anti-CD70 CAR γδ T cell therapy aimed at multiple solid and hematological cancers.

Positive

• Accepted presentation at a major international conference (EHA 2024) increases visibility.
• Focus on innovative ADI-270 therapy shows progress in pipeline development.
• Preclinical data could generate interest and partnerships if results are promising.

Negative

• Preclinical data might not translate into clinical success.
• No concrete financial data or expected timelines provided.
• Potential investor dilution if additional funding is required for further trials.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.

Details of the poster presentation are as follows:

Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Presenting Author: Yvan Chanthery, Ph.D.
Date & Time: June 14, 2024 at 18:00 CEST

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514346504/en/

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.

FAQ

What is ADI-270 in Adicet Bio's pipeline?

ADI-270 is an armored allogeneic anti-CD70 CAR γδ T cell therapy designed for multiple solid and hematological cancers.

When will Adicet Bio present ADI-270 data?

The presentation will be on June 14, 2024, at 18:00 CEST during the European Hematology Association Hybrid Congress.

Where is the EHA 2024 Hybrid Congress held?

The EHA 2024 Hybrid Congress will be held in Madrid, Spain, from June 13-16, 2024.

Who will present ADI-270 preclinical data at the EHA 2024?

Yvan Chanthery, Ph.D., will present the ADI-270 preclinical data.

What is the significance of ADI-270's presentation for Adicet Bio?

The presentation at EHA 2024 increases visibility and may attract interest from investors and partners.